Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees32,842IPOJan 15, 2018HQ124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
51.8%
Operating Margin
22.9%
EBITDA Margin
18.3%
Net Margin
8.2%
OCF Margin
9.6%
FCF Margin
6.7%
Returns on Capital
ROE
21.0%
ROA
3.6%
ROIC
11.7%
ROCE
7.8%
ROC (Greenblatt)
43.6%
3Y ROIIC
−41.6%
Consistency
Years Profitable / 10Y
3
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
26.68
Forward P/E
11.41
P/E ex-NRI
10.96
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
32.67
P/OCF
22.70
P/Owner Earnings
—
FCF Yield
3.08%
Enterprise Value Multiples
EV / EBIT
23.59
EV / Forward EBIT
24.64
EV / EBITDA
16.09
EV / Forward EBITDA
17.06
EV / Revenue
2.94
EV / Forward Revenue
3.09
Asset / Sales
P/S
2.16
P/B
4.65
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
0.00%
Forward Dividend Yield
0.00%
3Y Dividend Growth
0.0%
Payout Ratio
0.00
5Y Yield on Cost
0.00%
Buybacks & Dilution
3Y Buyback Ratio
−1.20%
Combined
Shareholder Yield
5.09%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
2.16
Gross Debt / EBITDA
5.42
Cash / Debt
0.21
Equity / Assets
0.19
Coverage
Interest Coverage
4.25
Short-Term Liquidity
Current Ratio
1.04
Quick Ratio
0.80
Cash Ratio
0.26
Composite Scores
Piotroski F-Score
8
Altman Z-Score
0.82
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
No dividend history found.
Date
Transcript
Type
2026-07-29
Q2 2026 Teva Pharmaceutical Industries Limited.. Earnings Call Transcript
Earnings Call
2026-07-07
Teva Pharmaceutical Industries Limited..To Discuss IL-15 Vitiligo Phase 1b 24 Week Efficacy Results Transcript
Corporate Presentation
2026-06-08
Teva Pharmaceutical Industries Limited.. at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-12
Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-29
Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-03-10
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-01-28
Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-01-13
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-04
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Conference Presentations
2025-11-05
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
10 of 55
5-Step DuPont Analysis
ROE %
21.22%
×
×
Net Margin %
8.16%
×
×
Operating Margin %
22.88%
Operating Income
$3.95B
÷
Revenue
$17.26B
×
Tax Burden
1.1521
Net Income
$1.41B
÷
Pretax Income
$1.22B
×
Interest Burden
0.3097
Pretax Income
$1.22B
÷
Operating Income
$3.95B
×
Asset Turnover
0.43
÷
Revenue
$17.26B
÷
Average Total Assets
$40.04B
Begin Total Assets
$39.33B
End Total Assets
$40.75B
×
Equity Multiplier
6.03
÷
Avg Total Assets
$40.04B
÷
Avg Stockholders Equity
$6.64B
Begin Equity
$5.37B
End Equity
$7.91B